Evidence map›Paper›PMID 35655246›Full record

ArticleResearch involvement and engagement2022

A practical 'How-To' Guide to plain language summaries (PLS) of peer-reviewed scientific publications: results of a multi-stakeholder initiative utilizing co-creation methodology.

Laura Dormer, Thomas Schindler, Lauri Arnstein Williams, Dawn Lobban, Sheila Khawaja, Amanda Hunn, Daniela Luzuriaga Ubilla, Ify Sargeant, Anne-Marie Hamoir

Abstract read
In one paragraph

Article in Research involvement and engagement, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Laura DormerFuture Science Group, London, UK.ORCID http://orcid.org/0000-0002-4868-8655
Thomas SchindlerBoehringer Ingelheim Pharma GmbH & Co. KG, Biberach a. d. Riss, Germany.ORCID http://orcid.org/0000-0002-7845-3048
Lauri Arnstein WilliamsEnvision Pharma Group, London, UK.
Dawn LobbanEnvision Pharma Group, Wilmslow, UK.ORCID http://orcid.org/0000-0002-3312-4857
Sheila KhawajaWorld Alliance of Pituitary Organizations, Zeeland, The Netherlands.
Amanda HunnA J Hunn Associates, London, UK.
Daniela Luzuriaga UbillaPatient Focused Medicines Development, The Synergist, Brussels, Belgium.
Ify SargeantTwist Medical, Burlingame, CA, USA.ORCID http://orcid.org/0000-0003-4779-4007
Anne-Marie HamoirPatient Focused Medicines Development, The Synergist, Brussels, Belgium. pfmd@thesynergist.org.ORCID http://orcid.org/0000-0002-9898-5703

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPeer-reviewed scientific publications and congress abstracts are typically written by scientists for specialist audiences; however, patients and other non-specialists are understandably interested in the potential implications of research and what they may mean for them. Plain language summaries (PLS)-summaries of scientific articles in easy-to-read language-are emerging as a valuable addition to traditional scientific publications. Co-creation of PLS with the intended audience is key to ensuring a successful outcome, but practical guidance on how to achieve this has been lacking.

methodsBuilding on the Patient Engagement (PE) Quality Guidance previously developed by Patient Focused Medicines Development (PFMD), a multi-stakeholder working group (WG) of individuals with patient engagement experience and/or expertise in PLS was established to develop further activity-specific guidance. PLS guidance was developed through a stepwise approach that included several rounds of co-creation, public consultation (two rounds), internal review and a final external review. The iterative development process incorporated input from a wide variety of stakeholders (patient representatives, industry members, publishers, researchers, medical communications agencies, and public officials involved in research bodies). Feedback from each step was consolidated by the WG and used for refining the draft guidance. The final draft was then validated through external consultation.

resultsThe WG comprised 14 stakeholders with relevant experience in PE and/or PLS. The WG developed a set of 15 ethical principles for PLS development. These include the necessity for objective reporting and the absence of any promotional intent, the need for balanced presentation, the importance of audience focus, the need to apply health literacy principles, and the importance of using inclusive and respectful language. The first public consultation yielded 29 responses comprising 478 comments or edits in the shared draft guidance. The second public consultation was an online survey of 14 questions which had 32 respondents. The final 'How-To' Guide reflects feedback received and provides a rational, stepwise breakdown of the development of PLS.

conclusionsThe resulting 'How-To' Guide is a standalone, practical, ready-to-use tool to support multi-stakeholder co-creation of PLS.

Indexed as

Patient engagementPlain language summaryScientific publication

Identifiers

PMID35655246
PMCPMC9164486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.